HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Marinus Pharma (NASDAQ:MRNS), maintaining a $27 price target. This reaffirms the firm's positive outlook on the company.
March 26, 2024 | 10:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Marinus Pharma with a $27 price target, indicating a strong positive outlook.
The reiteration of a Buy rating and maintenance of a $27 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100